NOR-SOLIDARITY Annals of Internal Medicine review report

Inge Christoffer Olsen, PhD

25 April, 2021

Table of Contents

# Introduction

This is the report for the review from Annals of Internal Medicine of the primary article. This report is based on an export from Viedoc dated “2020-10-16 08:41:09” system time stamped “ous\_20201016\_084109”. While the results are based on real data, the treatment allocation has been drawn randomly for this report. Thus, this is a mock-up report intended to show how the final report will look like, without showing the actual results of the trial and the treatment differences. There were 181 included patients.

# 11. Discharged to

This is an answer to stats reviewer point no 11. “11. Please state whether any cases were discharged to other sites (e.g., hospice)?”

Discharged to (FAS)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Discharged to | Standard of care (SOC) | Hydroxychloroquine + SOC | Remdesivir + SOC | Total |
| Home | 64 | 37 | 28 | 129 |
| Home, requiring municipal assistance | 3 | 3 | 2 | 8 |
| Recreation stay | 3 | 2 | 3 | 8 |
| Municipal rehabilitation/nursing home | 8 | 4 | 5 | 17 |
| Local hospital | 1 | 0 | 0 | 1 |
| NA | 8 | 6 | 4 | 18 |

Discharged to (FAS) in HCQ

|  |  |  |  |
| --- | --- | --- | --- |
| Discharged to | Standard of care (SOC) | Hydroxychloroquine + SOC | Total |
| Home | 43 | 37 | 80 |
| Home, requiring municipal assistance | 0 | 3 | 3 |
| Recreation stay | 2 | 2 | 4 |
| Municipal rehabilitation/nursing home | 4 | 4 | 8 |
| Local hospital | 1 | 0 | 1 |
| NA | 4 | 6 | 10 |

Discharged to (FAS) in Remdesivir

|  |  |  |  |
| --- | --- | --- | --- |
| Discharged to | Standard of care (SOC) | Remdesivir + SOC | Total |
| Home | 42 | 28 | 70 |
| Home, requiring municipal assistance | 3 | 2 | 5 |
| Recreation stay | 1 | 3 | 4 |
| Municipal rehabilitation/nursing home | 6 | 5 | 11 |
| NA | 5 | 4 | 9 |

# 21 Missing data

This is answer to stats reviewer point no 21: “21. Table 1. Please include the number missing for each variable.”

Missing values, all arms (FAS)

|  |  |  |  |
| --- | --- | --- | --- |
| Parameter | SOC (N=87) | SOC + HCQ (N=52) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |  |
| Age (years) | 0 (0%) | 0 (0%) | 0 (0%) |
| Female, n (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Body Mass Index (kg/m2) | 10 (11.5%), 10 (11.5%) | 3 (5.8%), 3 (5.8%) | 4 (9.5%), 4 (9.5%) |
| Symptoms prior to admission (days) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| P/F-ratio at admittance (kPa) | 0 (0%) | 2 (3.8%) | 0 (0%) |
| P/F-ratio < 40kPa, n (%) | 0 (0%) | 2 (3.8%) | 0 (0%) |
| Temperature (°C) | 0 (0%) | 0 (0%) | 0 (0%) |
| Respiratory rate (breaths/min) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ward, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Admitted to ICU, n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Moderate disease state (4-5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6-9), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (5), n(%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Comorbidities** |  |  |  |
| Chronic cardiac disease, including congenital heart disease | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Chronic pulmonary disease, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Ever smoking, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Hypertension, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Diabetes, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Obese (BMI > 30 kg/m2), n(%) | 10 (11.5%) | 3 (5.8%) | 4 (9.5%) |
| **Co-medications** |  |  |  |
| Steroids | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| Other immunomodulatory drugs | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| ACE inhibitor | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| AT-II blockers | 1 (1.1%) | 0 (0%) | 1 (2.4%) |
| **Hematology** |  |  |  |
| Hemoglobin (g/dL) | 1 (1.1%) | 1 (1.9%) | 1 (2.4%) |
| WBC (x109/L) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Neutrophils (x109/L) | 5 (5.7%) | 2 (3.8%) | 3 (7.1%) |
| Lymphocytes (x109/L) | 5 (5.7%) | 2 (3.8%) | 2 (4.8%) |
| Platelet counts (x10^9/L) | 1 (1.1%) | 1 (1.9%) | 1 (2.4%) |
| **Inflammatory markers** |  |  |  |
| CRP (mg/L) | 1 (1.1%) | 1 (1.9%) | 0 (0%) |
| Procalcitonin (µg/L) | 28 (32.2%) | 21 (40.4%) | 9 (21.4%) |
| Ferritin (µg/L) | 6 (6.9%) | 3 (5.8%) | 0 (0%) |
| **Other** |  |  |  |
| LDH (U/L) | 6 (6.9%) | 1 (1.9%) | 1 (2.4%) |
| D-dimer (mg/L FEU) | 11 (12.6%) | 6 (11.5%) | 2 (4.8%) |
| AST | 6 (6.9%) | 3 (5.8%) | 2 (4.8%) |
| ALT | 3 (3.4%) | 3 (5.8%) | 2 (4.8%) |
| eGFR (mL/min/1.73 m2) | 0 (0%) | 1 (1.9%) | 0 (0%) |
| **Viral count** |  |  |  |
| Viral count (log10 counts/1000 cells) | 21 (24.1%) | 17 (32.7%) | 10 (23.8%) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |  |
| Sero converted (RBD ≥ 5) | 28 (32.2%) | 17 (32.7%) | 9 (21.4%) |
| Sero converted (Capsid ≥ 10) | 28 (32.2%) | 17 (32.7%) | 9 (21.4%) |
| **Supplementary baseline information** |  |  |  |
| Systolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Diastolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| Mean Arterial Blood Pressure (mmHg) | 0 (0%) | 0 (0%) | 0 (0%) |
| SOFA score | 7 (8%) | 2 (3.8%) | 2 (4.8%) |
| Chronic kidney disease, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Autoimmune disease, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Cognitive impairment/dementia, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Neurological disorder, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Cancer, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Asthma, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| HIV, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) | 1 (2.4%) |

Missing values, HCQ (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=54) | SOC + HCQ (N=52) |
| **Demographics** |  |  |
| Age (years) | 0 (0%) | 0 (0%) |
| Female, n (%) | 0 (0%) | 0 (0%) |
| Body Mass Index (kg/m2) | 4 (7.4%), 4 (7.4%) | 3 (5.8%), 3 (5.8%) |
| Symptoms prior to admission (days) | 0 (0%) | 0 (0%) |
| P/F-ratio at admittance (kPa) | 0 (0%) | 2 (3.8%) |
| P/F-ratio < 40kPa, n (%) | 0 (0%) | 2 (3.8%) |
| Temperature (°C) | 0 (0%) | 0 (0%) |
| Respiratory rate (breaths/min) | 0 (0%) | 0 (0%) |
| Admitted to ward, n(%) | 0 (0%) | 0 (0%) |
| Admitted to ICU, n(%) | 0 (0%) | 0 (0%) |
| WHO Moderate disease state (4-5), n(%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6-9), n(%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6), n(%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (5), n(%) | 0 (0%) | 0 (0%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 0 (0%) | 0 (0%) |
| Chronic pulmonary disease, n(%) | 0 (0%) | 0 (0%) |
| Ever smoking, n(%) | 0 (0%) | 0 (0%) |
| Hypertension, n(%) | 0 (0%) | 0 (0%) |
| Diabetes, n(%) | 0 (0%) | 0 (0%) |
| Obese (BMI > 30 kg/m2), n(%) | 4 (7.4%) | 3 (5.8%) |
| **Co-medications** |  |  |
| Steroids | 0 (0%) | 0 (0%) |
| Other immunomodulatory drugs | 0 (0%) | 0 (0%) |
| ACE inhibitor | 0 (0%) | 0 (0%) |
| AT-II blockers | 0 (0%) | 0 (0%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 0 (0%) | 1 (1.9%) |
| WBC (x109/L) | 0 (0%) | 0 (0%) |
| Neutrophils (x109/L) | 3 (5.6%) | 2 (3.8%) |
| Lymphocytes (x109/L) | 3 (5.6%) | 2 (3.8%) |
| Platelet counts (x10^9/L) | 1 (1.9%) | 1 (1.9%) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 0 (0%) | 1 (1.9%) |
| Procalcitonin (µg/L) | 19 (35.2%) | 21 (40.4%) |
| Ferritin (µg/L) | 4 (7.4%) | 3 (5.8%) |
| **Other** |  |  |
| LDH (U/L) | 4 (7.4%) | 1 (1.9%) |
| D-dimer (mg/L FEU) | 7 (13%) | 6 (11.5%) |
| AST | 4 (7.4%) | 3 (5.8%) |
| ALT | 2 (3.7%) | 3 (5.8%) |
| eGFR (mL/min/1.73 m2) | 0 (0%) | 1 (1.9%) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 11 (20.4%) | 17 (32.7%) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| Sero converted (RBD ≥ 5) | 17 (31.5%) | 17 (32.7%) |
| Sero converted (Capsid ≥ 10) | 17 (31.5%) | 17 (32.7%) |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) |
| Diastolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) |
| Mean Arterial Blood Pressure (mmHg) | 0 (0%) | 0 (0%) |
| SOFA score | 1 (1.9%) | 2 (3.8%) |
| Chronic kidney disease, n(%) | 0 (0%) | 0 (0%) |
| Autoimmune disease, n(%) | 0 (0%) | 0 (0%) |
| Cognitive impairment/dementia, n(%) | 0 (0%) | 0 (0%) |
| Neurological disorder, n(%) | 0 (0%) | 0 (0%) |
| Cancer, n(%) | 0 (0%) | 0 (0%) |
| Cirrhosis, n(%) | 0 (0%) | 0 (0%) |
| Asthma, n(%) | 0 (0%) | 0 (0%) |
| HIV, n(%) | 0 (0%) | 0 (0%) |
| Active TB, n(%) | 0 (0%) | 0 (0%) |

Missing values, Remdesevir (FAS)

|  |  |  |
| --- | --- | --- |
| Parameter | SOC (N=57) | SOC + Remdesivir (N=42) |
| **Demographics** |  |  |
| Age (years) | 0 (0%) | 0 (0%) |
| Female, n (%) | 0 (0%) | 0 (0%) |
| Body Mass Index (kg/m2) | 8 (14%), 8 (14%) | 4 (9.5%), 4 (9.5%) |
| Symptoms prior to admission (days) | 0 (0%) | 1 (2.4%) |
| P/F-ratio at admittance (kPa) | 0 (0%) | 0 (0%) |
| P/F-ratio < 40kPa, n (%) | 0 (0%) | 0 (0%) |
| Temperature (°C) | 0 (0%) | 0 (0%) |
| Respiratory rate (breaths/min) | 0 (0%) | 0 (0%) |
| Admitted to ward, n(%) | 0 (0%) | 0 (0%) |
| Admitted to ICU, n(%) | 0 (0%) | 0 (0%) |
| WHO Moderate disease state (4-5), n(%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6-9), n(%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (6), n(%) | 0 (0%) | 0 (0%) |
| WHO Severe disease state (5), n(%) | 0 (0%) | 0 (0%) |
| **Comorbidities** |  |  |
| Chronic cardiac disease, including congenital heart disease | 0 (0%) | 1 (2.4%) |
| Chronic pulmonary disease, n(%) | 0 (0%) | 1 (2.4%) |
| Ever smoking, n(%) | 0 (0%) | 1 (2.4%) |
| Hypertension, n(%) | 0 (0%) | 1 (2.4%) |
| Diabetes, n(%) | 0 (0%) | 1 (2.4%) |
| Obese (BMI > 30 kg/m2), n(%) | 8 (14%) | 4 (9.5%) |
| **Co-medications** |  |  |
| Steroids | 1 (1.8%) | 1 (2.4%) |
| Other immunomodulatory drugs | 1 (1.8%) | 1 (2.4%) |
| ACE inhibitor | 1 (1.8%) | 1 (2.4%) |
| AT-II blockers | 1 (1.8%) | 1 (2.4%) |
| **Hematology** |  |  |
| Hemoglobin (g/dL) | 1 (1.8%) | 1 (2.4%) |
| WBC (x109/L) | 0 (0%) | 1 (2.4%) |
| Neutrophils (x109/L) | 4 (7%) | 3 (7.1%) |
| Lymphocytes (x109/L) | 4 (7%) | 2 (4.8%) |
| Platelet counts (x10^9/L) | 1 (1.8%) | 1 (2.4%) |
| **Inflammatory markers** |  |  |
| CRP (mg/L) | 1 (1.8%) | 0 (0%) |
| Procalcitonin (µg/L) | 18 (31.6%) | 9 (21.4%) |
| Ferritin (µg/L) | 3 (5.3%) | 0 (0%) |
| **Other** |  |  |
| LDH (U/L) | 5 (8.8%) | 1 (2.4%) |
| D-dimer (mg/L FEU) | 8 (14%) | 2 (4.8%) |
| AST | 5 (8.8%) | 2 (4.8%) |
| ALT | 2 (3.5%) | 2 (4.8%) |
| eGFR (mL/min/1.73 m2) | 0 (0%) | 0 (0%) |
| **Viral count** |  |  |
| Viral count (log10 counts/1000 cells) | 12 (21.1%) | 10 (23.8%) |
| **Anti-SARS-CoV-2 Antibodies** |  |  |
| Sero converted (RBD ≥ 5) | 18 (31.6%) | 9 (21.4%) |
| Sero converted (Capsid ≥ 10) | 18 (31.6%) | 9 (21.4%) |
| **Supplementary baseline information** |  |  |
| Systolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) |
| Diastolic Blood Pressure (mmHg) | 0 (0%) | 0 (0%) |
| Mean Arterial Blood Pressure (mmHg) | 0 (0%) | 0 (0%) |
| SOFA score | 6 (10.5%) | 2 (4.8%) |
| Chronic kidney disease, n(%) | 0 (0%) | 1 (2.4%) |
| Autoimmune disease, n(%) | 0 (0%) | 1 (2.4%) |
| Cognitive impairment/dementia, n(%) | 0 (0%) | 1 (2.4%) |
| Neurological disorder, n(%) | 0 (0%) | 1 (2.4%) |
| Cancer, n(%) | 0 (0%) | 1 (2.4%) |
| Cirrhosis, n(%) | 0 (0%) | 1 (2.4%) |
| Asthma, n(%) | 0 (0%) | 1 (2.4%) |
| HIV, n(%) | 0 (0%) | 1 (2.4%) |
| Active TB, n(%) | 0 (0%) | 1 (2.4%) |

# 25 Post-hoc power calculations

Anwer to stats review no 25: “25. This study had a small sample size. This should be stressed in the limitations. The authors state”there are no pre-assessment calculations of sample size needed nor the assumed power to detect a clinically meaningful treatment effect. " For the primary outcome(s), given the accrued sample sizes, please provide the readers with insight into how large a true between-arm effect size would need to be to produce 80% power."

We calculate the effect size needed to show a difference when we assume the mortality probability is 0.07 in the active group.

##   
## Two-sample comparison of proportions power calculation   
##   
## n = 50  
## p1 = 0.07  
## p2 = 0.2805295  
## sig.level = 0.05  
## power = 0.8  
## alternative = two.sided  
##   
## NOTE: n is number in \*each\* group

From the calculations we see that in a new trial we would need an absolute treatment difference in probability of death of 0.21 or 21% to reach 80% power with a sample size of 50 in each group.

# 7 Cox regression hazard ratio calculations

Answer to Statistical review comment no 7: “7. Please calculate hazard ratios via Cox models, and delete the”The natural logarithm of the average mortality rate ratio (logeRR) was estimated using the (O-E)/V estimator from the log-rank statistic with 95 % confidence intervals estimated using a normal distribution with 1/V as variance“.”

Cox hazard ratio estimates and corresponding p-values


|  |  |  |
| --- | --- | --- |
| Timeframe, Population | Hazard ratio | P-value |
| Full timeframe, All | Not applicable | 0.761 |
| Full timeframe, Hydroxychloroquine only | 3.11 (95% CI 0.28 to 34.35) | 0.354 |
| Full timeframe, Remdesivir only | 1.01 (95% CI 0.35 to 2.92) | 0.981 |
| Censored at 60 days, All | Not applicable | 0.563 |
| Censored at 60 days, Hydroxychloroquine only | 8.15 (95% CI 0.37 to 180.68) | 0.185 |
| Censored at 60 days, Remdesivir only | 1.25 (95% CI 0.4 to 3.86) | 0.704 |
| Censored at 28 days, All | Not applicable | 0.558 |
| Censored at 28 days, Hydroxychloroquine only | 8.15 (95% CI 0.37 to 180.68) | 0.185 |
| Censored at 28 days, Remdesivir only | 0.57 (95% CI 0.12 to 2.85) | 0.497 |

# 8 Box-plots

This is an answer to stats point 8

1. In sensitivity analyses, please include the results of some relatively simple between-arm comparisons for continuous outcomes (e.g. boxplots of the arithmetic change in the outcome from baseline to day 7 and baseline to day 10 by arm, with between-arm comparisons of these temporal changes using t-tests or Wilcoxon tests).

## Viral load




T-test HCQ

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | df | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 18 | 17 | -1.1880155 | 32.20030 | 0.244 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 17 | 10 | -0.0576418 | 17.41063 | 0.955 |

Wilcoxon test HCQ

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 18 | 17 | 138.5 | 0.644 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 17 | 10 | 94.0 | 0.675 |




T-test remdesivir

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | df | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 18 | 17 | -1.1880155 | 32.20030 | 0.244 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 17 | 10 | -0.0576418 | 17.41063 | 0.955 |

Wilcoxon test remdesivir

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 18 | 17 | 138.5 | 0.644 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 17 | 10 | 94.0 | 0.675 |

## PF-ratio




T-test HCQ

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | df | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 31 | 31 | 0.5286818 | 57.90534 | 0.599 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 22 | 23 | 0.3496140 | 42.93537 | 0.728 |

Wilcoxon test HCQ

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 31 | 31 | 532 | 0.475 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 22 | 23 | 277 | 0.597 |



T-test remdesivir

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | df | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 31 | 31 | 0.5286818 | 57.90534 | 0.599 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 22 | 23 | 0.3496140 | 42.93537 | 0.728 |

Wilcoxon test remdesivir

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Timepoint | .y. | group1 | group2 | n1 | n2 | statistic | p |
| diff\_7 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 31 | 31 | 532 | 0.475 |
| diff\_10 | value | Standard of care (SOC) | Hydroxychloroquine + SOC | 22 | 23 | 277 | 0.597 |

# 23 Number under observation

1. Figure 2: Please present the number of patients under observation at each time point separately by arm.

Counts for HCQ

|  |  |  |
| --- | --- | --- |
| Treatment | Period | Number with non-missing values |
| Standard of care (SOC) | Baseline | 44 |
| Standard of care (SOC) | Day 1 to 5 | 32 |
| Standard of care (SOC) | Day 6 to 10 | 19 |
| Standard of care (SOC) | Day 11 to 15 | 8 |
| Hydroxychloroquine + SOC | Baseline | 36 |
| Hydroxychloroquine + SOC | Day 1 to 5 | 35 |
| Hydroxychloroquine + SOC | Day 6 to 10 | 18 |
| Hydroxychloroquine + SOC | Day 11 to 15 | 6 |

Counts for remdesivir

|  |  |  |
| --- | --- | --- |
| Treatment | Period | Number of patients with non-missing values |
| Standard of care (SOC) | Baseline | 53 |
| Standard of care (SOC) | Day 1 to 5 | 41 |
| Standard of care (SOC) | Day 6 to 10 | 23 |
| Standard of care (SOC) | Day 11 to 15 | 13 |
| Remdesivir + SOC | Baseline | 36 |
| Remdesivir + SOC | Day 1 to 5 | 32 |
| Remdesivir + SOC | Day 6 to 10 | 23 |
| Remdesivir + SOC | Day 11 to 15 | 7 |